彭布罗利珠单抗
医学
不利影响
内科学
肺癌
荟萃分析
肿瘤科
随机对照试验
化疗
癌症
免疫疗法
作者
Tianyao Gong,Lei Liu,Yufei Liu,Haibo Liu,Yang Yang,Liuying Li,Chuantao Zhang
标识
DOI:10.1080/1120009x.2021.2014714
摘要
We conducted a meta-analysis to systematically review the efficacy and safety of pembrolizumab for advanced NSCLC. Databases were searched for randomized controlled trials (RCTs) treated with pembrolizumab till July 2021. Seven RCTs and 3988 patients were included. Our analysis suggests that pembrolizumab was more effective at improving PFS (HR, 0.59; 95% CI: 0.43-0.79; p = 0.0005), OS (HR, 0.65; 95% CI: 0.55-0.76; p < 0.00001) and ORR (RR, 1.85; 95% CI: 1.64-2.09; p < 0.00001) than chemotherapy. Patients with higher PD-L1 expression level were tend to have a better PFS, OS and ORR. Combination therapy of pembrolizumab was superior to pembrolizumab monotherapy in enhancing PFS. Pembrolizumab did not increase the frequency of commonly reported adverse events, but the immune-related adverse events (irAEs) occurred more frequently in the pembrolizumab group than those in the chemotherapy group. The pembrolizumab significantly improved the PFS, OS and ORR, simultaneously increasing the irAEs.
科研通智能强力驱动
Strongly Powered by AbleSci AI